Skip to main content
Aura Biosciences, Inc. logo

Aura Biosciences, Inc. — Investor Relations & Filings

Ticker · AURA ISIN · US05153U1079 US Manufacturing
Open in API
Filings indexed 323 across all filing types
Latest filing 2023-10-05 Director's Dealing
Country US United States of America
Listing US AURA

About Aura Biosciences, Inc.

https://aurabiosciences.com/

Aura Biosciences is a clinical-stage biotechnology company developing a new class of targeted therapies for solid tumors. The company's proprietary platform creates Virus-Like Drug Conjugates (VDCs), which use Virus-Like Particles to selectively deliver anti-cancer agents to tumor cells. This approach is designed to destroy cancer while preserving healthy tissue and organ function. Aura's initial focus is on ocular and urologic oncology, with a lead program for the first-line treatment of choroidal melanoma, a rare, vision-threatening eye cancer that lacks approved drug therapies. The company aims to establish a new standard of care across multiple cancer indications.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2023-10-05 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events that shareholders should know about. The content focuses on the appointment of a new Chief Medical Officer and the departure of the previous one, including details about employment agreements, severance, and related arrangements. There are no financial statements or quarterly/yearly financial results presented. The document is not an earnings release, annual report, or interim report. It is clearly an announcement of changes in senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence level.
2023-10-02 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 9, 2023, for Aura Biosciences, Inc. It announces the issuance of a press release with financial results for the quarter ended June 30, 2023, and also mentions an updated corporate presentation. The document itself does not contain the financial results or detailed financial statements but rather furnishes the press release and presentation as exhibits. The text explicitly states that the press release is furnished as an exhibit and is not deemed filed for certain legal purposes. The document is a current report announcing events and updates rather than the actual earnings release or detailed financial report. Given the nature of the document as a current report announcing financial results and a corporate presentation, the best classification is Earnings Release (ER), as the primary content is the announcement of quarterly financial results via a press release. Confidence is high because the document is a typical 8-K announcing quarterly earnings results and related materials.
2023-08-09 English
FORM 4 SUBMISSION
Director's Dealing
2023-06-09 English
FORM 4 SUBMISSION
Director's Dealing
2023-06-09 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.